Pfizer says its experimental drug for deadly condition that causes appetite and weight loss in cancer patients shows positive trial results
Publishing timestamp: 2024-09-14 12:45:01
Summary
Pfizer's experimental drug for cancer cachexia showed positive results in midstage trial, potentially becoming the first approved treatment for the condition. The drug, ponsegromab, improved body weight, muscle mass, quality of life, and physical function in patients. Pfizer is planning late-stage development and aims to start studies in 2025 for approval.
Sentiment: POSITIVE
Tickers: PFE,
Keywords: health care industry, business news, cancer, business, biotech and pharmaceuticals, breaking news: business, breaking news, science, pfizer inc, pharmaceuticals, biotechnology,